Beta-Thromboglobulin (βtg) and Platelet Factor 4 (PF₄) in Patients with Myeloproliferative Diseases

• References

• 1 Bellucci S, Ignarova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by level of plasma thrombomodulin, protein S, PAI-1, tPA and vWF. Thromb Haemost 1993; 70: 736-742
• 2 Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA. Studies of human α-granules release in vivo. Blood 1981; 58: 607-618
• 3 Randi ML, Fabris F, Casonato A, Girolami A. Different anticoagulant mixture and βtg and PF₄ . Thromb Haemost 1981; 46: 569
• 4 Luzzatto G, Fabris F, Mazzucato M, Girolami A. PF₄ versus βtg as evidence for platelet activation in myeloproliferative disorders. Scand J Haematol 1985; 35: 299-304
• 5 Stevanato F, Paolini R, Fabris F, Casonato A, Celia G. Effect of cellulose acetate 0.2 μm filter on platelet specific proteins plasma levels. Folia Haematol 1990; 3: 377-381
• 6 Kaplan KL, Owen J. Plasma levels of Beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202
• 7 Lane DA, Ireland S, Wolff S, Ranasinghe E, Dawes J. Detection of enhanced in vivo platelet a-granules release in different patient groups. Comparison of β-thromboglobulin, platelet factor 4 and thrombospondin Thromb Haemost 1984; 52: 183-187
• 8 Hirsch J. Laboratory diagnosis of thrombosis in. Colman RW, Hirsh J, Marder VJ. et al. (eds) Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott; 1987: 1165-1183